Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

3 Nov 2016 07:47

RNS Number : 2256O
GW Pharmaceuticals PLC
03 November 2016
 

 

For filings with the FCA include the annex

 

For filings with issuer exclude the annex

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

GW Pharmaceuticals plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

Change in issuer's total voting rights

x

3. Full name of person(s) subject to thenotification obligation: iii

The Capital Group Companies, Inc.

4. Full name of shareholder(s) (if different from 3.):iv

See Section 9

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

1 November 2016

6. Date on which issuer notified:

2 November 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

Below 15% - Aggregate of voting rights from shares

      
 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

ADRs

(US36197T1034)

3,778,439

45,341,270

 

 

45,341,270

 

14.9909%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

45,341,270

14.9909%

                 
 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Number of

Shares

Percent of Outstanding

The Capital Group Companies, Inc. ("CG") holdings

45,341,270

14.9909%

 

 

 

 

Holdings by CG Management Companies and Funds:

 

 

• Capital Guardian Trust Company1

 

 

• Capital Research and Management Company2

45,340,850

14.9908%

- SMALLCAP World Fund, Inc.3

23,716,800

7.8414%

    

 

1Indirect subsidiaries of Capital Research and Management Company.

2Subsidiary of The Capital Group Companies, Inc.

3Mutual fund managed by Capital Research and Management Company.

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will ceaseto hold:

 

12. Date on which proxy holder will cease to holdvoting rights:

 

 

13. Additional information:

 

14. Contact name:

Vivien Tan

15. Contact telephone number:

(213) 615-0469

   

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEAXFDELDKFEF
Date   Source Headline
22nd Jun 20162:22 pmRNSHolding(s) in Company
21st Jun 201612:00 pmRNSEpidiolex Development Program in Infantile Spasms
17th Jun 20165:05 pmRNSHolding(s) in Company
8th Jun 20164:54 pmRNSHolding(s) in Company
31st May 20161:25 pmRNSTotal Voting Rights
31st May 201612:00 pmRNSPresents at Goldman Sachs and Jefferies Conference
16th May 201612:00 pmRNSGWP presenting at UBS Global Healthcare Conference
13th May 20163:50 pmRNSDirector/PDMR Shareholding
11th May 20165:19 pmRNSDirector/PDMR Shareholding
5th May 201612:00 pmRNSHalf-year Report
4th May 201612:00 pmRNSPresenting at BoAML 2016 Healthcare Conference
29th Apr 20161:37 pmRNSTotal Voting Rights
28th Apr 201612:00 pmRNSNotice of Results
21st Apr 201612:00 pmRNSOrphan Drug Designation for Cannabidiol in TSC
11th Apr 201612:00 pmRNSInitiates Ph 3 Study in Tuberous Sclerosis Complex
1st Apr 20163:24 pmRNSDirector/PDMR Shareholding
23rd Mar 20165:07 pmRNSResult of AGM
18th Mar 20163:34 pmRNSBlock Listing Application
14th Mar 201611:00 amRNSEpidiolex Positive Phase 3 Pivotal Study Results
29th Feb 20169:26 amRNSTotal Voting Rights
22nd Feb 20166:16 pmRNSNotice of AGM
17th Feb 201610:37 amRNSBlocklisting Interim Review
15th Feb 20162:39 pmRNSDirector/PDMR Shareholding
10th Feb 201612:00 pmRNS1st Quarter Results
4th Feb 20163:45 pmRNSPresenting at Leerink Global Healthcare Conference
2nd Feb 20163:07 pmRNSNotice of Results
29th Jan 201611:42 amRNSTotal Issued Share Capital
29th Jan 20169:29 amRNSHolding(s) in Company
28th Jan 20168:47 amRNSHolding(s) in Company
25th Jan 20168:33 amRNSHolding(s) in Company
6th Jan 201612:01 pmRNSPublication of UK Annual Report and Accounts
31st Dec 201510:42 amRNSTOTAL ISSUED SHARE CAPITAL
29th Dec 20152:26 pmRNSDirector/PDMR Shareholding
24th Dec 201512:00 pmRNSLancet Neurology Publishes Epidiolex Data
22nd Dec 20155:14 pmRNSDirector/PDMR Shareholding
21st Dec 20156:22 pmRNSDirector/PDMR Shareholding
16th Dec 20154:16 pmRNSDirector/PDMR Shareholding
16th Dec 20159:27 amRNSDirector/PDMR Shareholding
8th Dec 20157:00 amRNSFinal Results
7th Dec 20156:00 pmRNSNew Physician Reports of Epidiolex Treatment
30th Nov 20151:00 pmRNSDate and Time Change for Q4 and FY 2015 Results
30th Nov 20159:38 amRNSTotal Voting Rights
25th Nov 20152:00 pmRNSEpidiolex data to be presented at AES Meeting
24th Nov 20156:00 pmRNSNotice of Results
24th Nov 20156:00 pmRNSPresenting at Piper Jaffray Healthcare Conference
2nd Nov 201510:09 amRNSTotal Voting Rights
27th Oct 201511:05 amRNSAgreement with NSW to Study Epidiolex and CBDV
27th Oct 201511:00 amRNSResults from Sativex Phase 3 Cancer Pain Trials
15th Sep 20152:00 pmRNSPositive Proof of Concept Data in Schizophrenia
10th Sep 20152:00 pmRNSPresenting at Two Upcoming Investor Conferences

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.